Antisense DNAs as targeted therapeutics for cancer: No longer a dream

Current Opinion in Investigational Drugs

Volumn 3, Issue 6, 2002, Pages 934-939

  Cho Chung, Yoon S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antisense; Cancer; Chemotherapy; Gene expression; Growth inhibition; Oligonucleotides

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; FOMIVIRSEN; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GTI 2040; IRINOTECAN; ISIS 2503; ISIS 3521; LR 3001; MAFOSFAMIDE; MG 98; NUCLEIC ACID; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PACLITAXEL; PROTEIN BCL 2; PROTEIN C MYB; PROTEIN C MYB ANTIBODY; PROTEIN KINASE C ALPHA; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOXICITY; ENZYME SUBUNIT; FATIGUE; FUTUROLOGY; GENE EXPRESSION; GENOMICS; HEMATOLOGIC DISEASE; HUMAN; IMMUNOTOXICITY; LIVER DYSFUNCTION; MAXIMUM TOLERATED DOSE; MEDICAL TECHNOLOGY; NONHUMAN; PROTEIN MOTIF; REVIEW; STRUCTURE ANALYSIS; THROMBOCYTOPENIA;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DNA, ANTISENSE; GENE EXPRESSION; HUMANS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE;

EID: 0036628388     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Stein C, Cheng Y-A: Antisense inhibition of gene expression. In: Cancer - Principles and Practice of Oncology. DeVita V, Rosenberg S, Hellman S (Ed), Lippincott Williams & Wilkins, New York, NY, USA (1997):3059-3074.
2. Agrawal S: Antisense oligonucleotides: Towards clinical trials. Trends Biotechnol (1996) 14:376-387.
3. Akhtar S, Agrawal S: In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci (1997) 18:12-18.
4. Bennett CF: Antisense oligonucleotides: Is the glass half full or half empty? Biochem Pharmacol (1998) 55:9-19 An excellent review in which the current status and future issues are discussed with respect to antisense therapeutics.
5. Agrawal S (Ed): Antisense Therapeutics. Humana Press, Totowa, NJ, USA (1996).
6. Stein C, Krieg A (Ed): Applied Antisense Oligonucleotide Technology. Wiley-Liss, New York, NY, USA (1998).
7. Crooke S (Ed): Antisense Research and Application. Springer-Verlag, Berlin, Germany (1998).
8. Wickstrom E (Ed): Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. Marcel Dekker, New York, NY, USA (1998).
9. Ciba Foundation Symposium: Oligonucleotides as Therapeutic Agents - Symposium No 209. J Wiley & Sons Inc, New York, NY, USA (1997).
10. Dorr F: Antisense oligonucleotides in the treatment of cancer. Antisense Nucleic Acid Drug Dev (1999) 9:391-396 An excellent and detailed review on clinical trials of antisense therapeutics.
11. Cho-Chung YS: Antisense and therapeutic oligonucleotides: Toward a gene-targeting cancer clinic. Exp Opin Ther Patents (2000) 10:1711-1724. A detailed review on patent development and basic research on antisense therapeutics.
12. Gewirtz AM: Oligonucleotide therapeutics: A step forward. J Clin Oncol (2000) 18:1809-1811. An excellent commentary on antisense drug development.
13. Tamm I, Dorken B, Hartmann G: Antisense therapy in oncology: New hope for an old idea? Lancet (2001) 358:489-497. An excellent on clinical development of antisense therapeutics.
14. Uhlmann E: Oligonucleotide technologies: Synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany. Expert Opin Biol Ther (2001) 1:319-328. An excellent review on the chemistry and clinical development of antisense therapeutics.
15. Dove A: Antisense and sensibility. Nat Biotechnol (2002) 20:121-124. An excellent review/commentary on the clinical application of antisense technology.
16. Bradbury AW, Carter DC, Miller WR, Cho-Chung YS, Clair T: Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer (1994) 69:738-742.
17. Miller WR, Watson DM, Jack W, Chetty U, Elton RA: Tumour cyclic AMP binding proteins. An independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat (1993) 26:89-94.
18. Simpson BJ, Ramage AD, Hulme MJ, Burns DJ, Katsaros D, Langdon SP, Miller WR: Cyclic adenosine 3′-5′-monophosphate-binding proteins in human ovarian cancer: Correlations with clinicopathological features. Clin Cancer Res (1996) 2:201-206.
19. McDaid HM, Cairns MT, Atkinson RJ, McAleer S, Harkin DP, Gilmore P, Johnston PG: Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer (1999) 79:933-939.
20. Tortora G, Yokozaki H, Pepe S, Clair T, Cho-Chung YS: Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc Natl Acad Sci USA (1991) 88:2011-2015.
21. Yokozaki H, Budillon A, Tortora G, Meissner S, Beaucage SL, Miki K, Cho-Chung YS: An antisense oligodeoxynucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res (1993) 53:868-872.
22. Cho-Chung YS, Nesterova M, Pepe S, Lee GR, Noguchi K, Srivastava RK, Srivastava AR, Alper O, Park YG, Lee YN: Antisense DNA-targeting protein kinase A-RIα subunit: A novel approach to cancer treatment. Front Biosci (1999) 4:D898-907.
23. Srivastava RK, Srivastava AR, Seth P, Agrawal S, Cho-Chung YS: Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RIα subunit: p53-independent mechanism of action. Mol Cell Biochem (1999) 195:25-36.
24. Alper O, Hacker NF, Cho-Chung YS: Protein kinase A-Iα subunit-directed antisense inhibition of ovarian cancer cell growth: Crosstalk with tyrosine kinase signaling pathway. Oncogene (1999) 18:4999-5004.
25. Nesterova M, Cho-Chung YS: Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIα subunit. Antisense Nucleic Acid Drug Dev (2000) 10:423-433. One of the first suggestions of a mechanism by which antisense technology directed against protein kinase A inhibited tumor cell growth through modulation of the signal-transduction network.
26. Nesterova M, Cho-Chung YS: A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat Med (1995) 1:528-533.
27. Zhang R, Zeng XF, Bowman JD, Agrawal S: Growth inhibition of human lung cancer A549 xenografts in nude mice following oral administration of mixed-backbone oligonucleotides targeted at protein kinase A. Proc Am Assoc Cancer Res (1998) 39: Abs 3522
28. Nesterova M, Noguchi K, Park YG, Lee YN, Cho-Chung YS: Compensatory stabilization of RIIβ protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense- directed down-regulation of protein kinase A RIα protein. Clin Cancer Res (2000) 6:3434-3441. First report that antisense technology demonstrate target specificity in the intracellular compensatory mechanism for a key signal-transduction enzyme, protein kinase A.
29. Agarwal S, Zhao Q: Mixed backbone oligonucleotides: Improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev (1998) 8:135-139. A demonstration of the advantage of the use of modified oligonucleotides over phosphorothioate oligonucleotides on observed toxicity.
30. Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AR, Ciardiello F: Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res (2000) 6:2506-2512.
31. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL: Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol (1998) 18:3509-3517.
32. Yang WL, Iacono L, Tang WM, Chin KV: Novel function of the regulatory subunit of protein kinase A: Regulation of cytochrome c oxidase activity and cytochrome c release. Biochemistry (1998) 37:14175-14180.
33. Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F: Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res (2001) 7:2537-2544.
34. Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S, Cho-Chung YS: Protein kinase A RIα antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad- hypophosphorylation. Clin Cancer Res (2002) 8:607-614. Molecular proof that antisense blockade of an upstream signal-transduction molecule (PKA) leads to downstream cascade of the pathway, for example, apoptosis.
35. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 270:467-470.
36. Cho YS, Kim MK, Cheadle C, Neary C, Becker KG, Cho-Chung YS: Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc Natl Acad Sci USA (2001) 98:9819-9823. The first demonstration of the genomic-scale view of antisense mechanism of action, which shows the sequence-specific modulation of global gene expression, and leads to the identification of clinically relevant antisense drugs.
37. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Kilnman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
38. Buolamwini JK: Novel anticancer drug discovery. Curr Opin Chem Biol (1999) 3:500-509.
39. Sharma HW, Hsiao R, Narayanan R: Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense Nucleic Acid Drug Dev (1996) 6:3-7.
40. Calabretta B, Skorski T: Targeting c-Myc in leukemia. Anticancer Drug Des (1997) 12:373-381.
41. Gewirtz AM: Antisense oligonucleotide therapeutics for human leukemia. Curr Opin Hematol (1998) 5:59-71.
42. Monia BP: First- and second-generation antisense inhibitors targeted to human c-Raf kinase: In vitro and in vivo studies. Anticancer Drug Des (1997) 12:327-339.
43. Geiger T, Muller M, Dean NM, Fabbro D: Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des (1998) 13:35-45.
44. Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res (2000) 6:1259-1266.
45. Cowsert LM: In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development. Anticancer Drug Des (1997) 12:359-371.
46. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, Di Stefano F, Cotter FE: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 18:1812-1823. A milestone paper on the discovery of the clinical efficacy of antisense bcl-2 in non-Hodgkin's lymphoma.
47. Luger SM, O'Brien SG, Ratajczak J, Ratajczak MZ, Mick R, Stadtmauer EA, Nowell PC, Goldman JM, Gewirtz AM: Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: A pilot study. Blood (2002) 99:1150-1158.
48. Klem R: Genasense™ (bcl-2 antisense oligodeoxynucleotide): An active anticancer agent. Oligonucleotides in Drug Discovery and Development, Long Branch, NJ, USA (2002) March 4-5.
49. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Holenstein U, Wolff K, Pehamberger H: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 356:1728-1733.
50. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes De Menezes DE, D'Aloisio S, Tolcher AW: A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res (2001) 7:3920-3927.
51. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G: C-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res (1998) 58:283-289.
52. Chen L, Agrawal S, Zhou W, Zhang R, Chen J: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA (1998) 95:195-200.
53. Tortora G, Caputo R, Damiano V, Bianco R, Pepe S, Bianco AR, Jiang Z, Agrawal S, Ciardiello F: Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci USA (1997) 94:12586-12591.
54. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem (1995) 270:2620-2627.
55. Fennewald SM, Rando RF: Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem (1995) 270:21718-21721.
56. Wang Y, Patel DJ: Solution structure of a parallel-stranded G-quadruplex DNA. J Mol Biol (1993) 234:1171-1183.
57. Wyatt JR, Stein CA: In: Applications of Antisense Therapies to Restenosis. Rabbani L (Ed), Kluwer Academic Publishers, Boston, MA, USA (1999).
58. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacteria DNA rapidly induces lymphocytes to secrete interleukin 6, interleukin 12, and interferon-γ. Proc Natl Acad Sci USA (1996) 93:2879-2883.
59. Zhao Q, Temsamani J, Zhou RZ, Agrawal S: Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev (1997) 7:495-502.
60. Krieg AM: Leukocyte stimulation by oligodeoxynucleotides. In: Applied Antisense Oligonucleotide Technology. Stein CA, Krieg AM (Ed), Wiley-Liss, New York, NY, USA (1998):431-448. An in-depth review of the CpG motif and its role in immune stimulation.
61. Pisetsky DS: Immune activation by bacterial DNA: A new genetic code. Immunity (1996) 5:303-310.
62. Hendrzak JA, Brunda MJ: Interleukin-12. Biologic activity, therapeutic utility, and role in disease. Lab Invest (1995) 72:619-637.
63. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL: "The good, the bad, and the ugly." The role of chemokines in models of human disease. J Immunol (1996) 156:3583-3586.
64. Agrawal S, Zhao Q: Antisense therapeutics. Curr Opin Chem Biol (1998) 2:519-528. An excellent review on the pharmacokinetics, side effects, toxicology and clinical application of antisense therapeutics.